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Background: Metastatic colorectal cancer (mCRC) may present various behaviours that define different courses of
tumor evolution. There is presently no available tool designed to assess tumor aggressiveness, despite the fact that
this is considered to have a major impact on patient outcome.
Methods/Design: CORIOLAN is a single-arm prospective interventional non-therapeutic study aiming mainly to assess
the natural tumor metabolic progression index (TMPI) measured by serial FDG PET-CT without any intercurrent
antitumor therapy as a prognostic factor for overall survival (OS) in patients with mCRC.
Secondary objectives of the study aim to test the TMPI as a prognostic marker for progression-free survival (PFS),
to assess the prognostic value of baseline tumor FDG uptake on PFS and OS, to compare TMPI to classical
clinico-biological assessment of prognosis, and to test the prognostic value on OS and PFS of MRI-based apparent
diffusion coefficient (ADC) and variation of vADC using voxel-based diffusion maps.
Additionally, this study intends to identify genomic and epigenetic factors that correlate with progression of tumors
and the OS of patients with mCRC. Consequently, this analysis will provide information about the signaling pathways
that determine the natural and therapy-free course of the disease. Finally, it would be of great interest to investigate
whether in a population of patients with mCRC, for which at present no known effective therapy is available, tumor
aggressiveness is related to elevated levels of circulating tumor cells (CTCs) and to patient outcome.
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Discussion: Tumor aggressiveness is one of the major determinants of patient outcome in advanced disease. Despite
its importance, supported by findings reported in the literature of extreme outcomes for patients with mCRC treated
with chemotherapy, no objective tool allows clinicians to base treatment decisions on this factor. The CORIOLAN study
will characterize TMPI using FDG-PET-based metabolic imaging of patients with chemorefractory mCRC during a period
of time without treatment. Results will be correlated to other assessment tools like DW-MRI, CTCs and circulating DNA,
with the aim to provide usable tools in daily practice and in clinical studies in the future.
Clinical trials.gov number: NCT01591590.
Keywords: Colorectal cancer, Progression rate assessment, FDG-PET, PET/CTBackground
Natural history of metastatic colorectal cancer
With an incidence rate of 35 per 100.000 per year, colorec-
tal cancer (CRC) affects about 150.000 people each year in
Western Europe. Although surgery is a potentially curative
treatment, about half of patients experience metastatic
spread of their disease [1], which, in the vast majority of
cases, leads to their death. Current management algorithms
in mCRC are based on anatomical considerations defining
the resectability of tumor spread, or clinical symptoms
(ECOG general status, number of metastatic sites, alkaline
phosphatase levels, transaminase levels).Clinical symptoms,
however, provide only a partial picture of the situation. To
date, the analysis of tumor biology, with the noticeable
exception of RAS mutations, which are of interest only
for anti-EGFR therapies, remains completely absent from
most decision-making about mCRC.
The natural history of mCRC tumors has been poorly
studied. However, a thorough review of the scientific litera-
ture highlights its importance. Six prospective, randomized
trials involving chemotherapy-free intervals in at least one
of the randomization arms [2-8] have been published, and
have enrolled 1149 patients whose treatment included a
therapeutic temporary delay until progression. These trials
can be classified into two types:
1) Studies comparing immediate versus delayed
chemotherapy in first-line mCRC, and
2) Studies comparing chemotherapy-free intervals until
clinical or radiological evidence of progression
versus chemotherapy maintenance in patients having
experienced disease control after 2 or 3 months of
induction therapy.
Trials using first-line chemotherapy [3,5,7] report
that 6% to 15% of tumors progress during the 2 to 3
months induction period, suggesting that these tumors
most probably have a chemo-refractory and an aggressive
phenotype.
By contrast, patients included in early trials at a time
when only 5-fluorouracil was available are reported to have
a median overall survival (OS) of 10 months. Interestingly,8% to 19% of them are still alive after 2 years [2,4]. It is
hypothesized that these patients bear slow-growing diseases
that are probably partially sensitive to chemotherapy.
Progression-free-survival (PFS) of patients with tumors
observed in a therapeutic window is usually measured at
3 to 6 months with large ranges from 0.1 to 30 months.
Those large ranges prefigure the differences between
several tumor subpopulations.
Moreover, two of the studies [3,5] show no correlation
between length of CFI and subsequent response to
chemotherapy, adding another indirect argument to
support the hypothesis that tumor’s natural evolution
and its sensitivity to chemotherapy mirror different
aspects of the tumor.
Formal study of the natural pace of tumor evolution
by classical means is difficult and, while additional evi-
dence is obviously needed, new tools able to discriminate
different paces of tumor growth must still be developed
and validated.Assessment of tumor metabolic progression index (TMPI)
The clinical evidence for tumor aggressiveness has never
been formally assessed in daily practice or in clinical stud-
ies and remains largely unpredictable. In both contexts,
the patient populations are composed of a wide array
of different tumor phenotypes evolving with different
outcomes while carrying the same apparent disease.
Tailoring treatment to the tumor aggressiveness requires
an objective and rapidly available mean to assess a tumor’s
behavior. One could hypothesize that the same tools used
to assess tumor response under therapy could also be used
to assess natural tumor growth independently of the treat-
ment given, for instance during a rest period. The most
frequently used RECIST-based radiological response as-
sessment has a definite but very limited descriptive value
of treatment benefit in cancer care [9-13]. New biological
drugs constitute an even greater challenge for classical
radiology because they seldom induce structural changes
to the tumor, underscoring the need to develop new diag-
nostic means to assess early drug-induced intra-tumoral
changes. Such new assessment methods could lead to new
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venting patient and tumor heterogeneity.
Several potential early response detection techniques are
emerging: serial FDG PET-CT; dynamic contrast-enhanced
MRI (DCE-MRI) and diffusion MR; and circulating tumor
cells (CTCs) and circulating tumor DNA [14] detection.
Among these, FDG PET-CT is the most studied and has
been found to be very promising. Its value in detecting
early metabolic changes, predictive of a therapy’s later
outcome, is currently widely assessed [15,16]. Recent
data suggest that serial FDG PET-CT tumor metabolic
assessment is a reliable tool for early detection of refrac-
tory disease, provided some conditions are fulfilled (e.g.,
tumor must be FDG-avid and lesions should be greater
than a defined minimal size).
Higashi et al.’s trials on ovarian cancer cell lines sug-
gest that FDG uptake does not relate to the proliferative
activity of cancer cells, but strongly relates to the number
of viable tumor cells [17]. If we know that the average
doubling of mCRC cells is about 92 days [18], and if we
accept that over time both cell volume and cellular glyco-
lytic activity increase while the interstitial volume remains
constant, then whole tumor FDG uptake should be
linearly correlated with the number of cells. Moreover, it
is important to detect tumors in their exponential growth
period (rather than linear growth), given that for PET
detectability there should be a minimal increase of 15% in
SUVmax to be significant; in this way, a 2-week interval
between two FDG PET-CT scans should be sufficient.
Previously, our research group prospectively included
42 patients with mCRC undergoing first- or second-line
chemotherapy in a study investigating serial FDG PET-CT.
FDG PET-CT was performed at baseline and 15 days
after the first cycle of chemotherapy. Data show excel-
lent correlation between the absence of metabolic re-
sponse at day 14 and the absence of structural response as
measured by CT Scan at 6 weeks, a modest correlation be-
tween metabolic and radiological response, and excellent
predictive value for metabolic response on PFS and overall
survival (OS) [19].
FDG PET-CT assessments
Some groups have performed serial FDG PET-CT im-
aging without intercurrent treatment in cancer patients
[20]. However, the aim of these studies was to determine
the cut-off for defining a significant metabolic response
or progression. The calculated variability in these studies
was probably contaminated by the inclusion of rapidly
progressing tumors that showed rapid FDG uptake
increases, which were falsely considered to reflect meas-
urement variability.
The variability of tumor FDG uptake measurement
performed after 2 weeks without any antitumor drug in-
terventions depends on several factors including 1) thevariability of the measure for technical reasons, 2) the
patient’s physiological conditions variations (e.g., insulin
levels, fluctuations in tumor blood flow) and 3) TMPI.
For the present study, it is of crucial importance that the
first two sources of variability are minimized using very
strict standardization of imaging.
The “technical” variability was found to be minimal
in lesions bigger than 2 cm and lesions with high FDG
uptake (high SUV).
Magnetic resonance imaging
Diffusion-weighted magnetic resonance imaging (DW-
MRI) is a technique used to reflect the microstructural
properties of tissues, related to the intra- and extra-cellular
motion of free water molecules, indicative of tissue cellu-
larity and structure. Measurement and quantification are
possible using the apparent diffusion coefficient (ADC) of
DW-MRI and have been linked to lesion aggressiveness
and tumor response, although the biophysical basis for
this is not completely understood. Hyper-cellularity
and increased nucleo-cytoplasmic ratio decrease ADC.
Necrosis and loss of cells tend to increase ADC values.
Parameters derived from DW-MRI are appealing as im-
aging biomarkers, because their acquisition is noninvasive.
Moreover, DW-MRI does not require any exogenous
contrast agents, does not use ionizing radiation, and
yet results are quantitative and can be obtained rela-
tively rapidly, being easily incorporated into routine
patient evaluations.
Changes in DW-MRI may be an effective early biomarker
for treatment outcome both for vascular disruptive drugs
and for therapies that induce apoptosis [21,22]. Suc-
cessful treatment is reflected by increases in ADC
values. DW-MRI has also been shown to prospectively
predict the success of some treatments in a number of
different tumors [23-25]. Recently, Morgan et al. showed
the potential of ADC variation over time to predict the
natural history of untreated prostate cancer [26].
Acquisition sequences for DWI are not completely
standardized, but basic techniques are well known and
available on systems from all major vendors. There is no
established standard for measurement of ADC but recent
reports promote voxel-based analysis and volumetric eval-
uation of ADC (vADC) which is well correlated with cellu-
larity, as shown in gliomas [27,28]. This method also carries
the advantages of being less operator-dependent and
more reproducible than ROI-based techniques. For a
monocentric study, the ADC calculation is reproducible
and robust over time. Longitudinal voxel-based measure-
ments seem well suited to treatment follow-up.
Next generation sequencing
Numerous studies have shown that the concentration of
circulating cell-free tumor DNA is higher in cancer
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naked DNA into the plasma after apoptosis or necrosis,
early in their development. Because this DNA can be
extracted from blood, the measurement of circulating
free DNA could be a potential new tool for cancer detec-
tion [14]. Moreover, the extracted DNA could be used to
detect genetic and epigenetic alterations through Next
Generation Sequencing (NGS) technologies that may
affect the important regulatory pathways in the pathology
of cancer.
Evaluating blood samples for mutant DNA is particu-
larly attractive, because it could be applicable in diverse
forms of cancer, including solid tumors, and because
blood samples could easily be collected during the clinical
follow-up of patients [29,30]. If one could show that
specific genomic rearrangements in plasma DNA pro-
vide a sensitive and specific measure of tumor growth
rate and that they can be used as an early biomarker of
disease prognosis and patient outcome, this may provide a
substantial advance in monitoring the disease burden in
patients with CRC. In a trial enrolling 30 metastatic breast
cancer patients, circulating tumor DNA provided the
earliest measure of treatment response in 10 of 19 women
(53%) when compared to CA 15–3 levels and the number
of circulating tumor cells (CTCs) measured at the identi-
cal time point [31]. This technology appears very promis-
ing for studying the clonal evolution of metastatic cancer
under therapy or during CFIs.
Assessement of circulating tumor cells
CTCs are cells that originate from a primary tumor and
circulate through the bloodstream. The FDA-approved
CellSearch® system enables CTC enrichment by using
antibody-coated magnetic beads. Previous studies have
shown that CTCs, which can be detected and analyzed
in a standardized, objective manner, may have prognos-
tic and predictive value in the metastatic cancer setting,
including metastatic breast [32,33] and colon cancer
[34-36]. It would be interesting to validate whether CTC
detection and quantification could serve as a clinically rele-
vant surrogate marker of tumor growth or aggressiveness
for the individual patient with mCRC.
Study hypothesis
We hypothesize that, in a population of patients with
mCRC for whom no known effective therapy is available,
tumor growth rate is related to patient outcome, and
that serial FDG PET-CT will be able to measure it. If
the hypothesis is verified, this finding could enable us
to define therapeutic strategies according to the TMPI
assessed by serial pre-therapeutic FDG-PET. It would
also limit the need for randomization in early drug
development phases, because patients could be considered
as their own control. Moreover, patients could be stratifiedaccording to their baseline metabolic growth rates in
randomized controlled trials having OS as endpoint.
Methods
Study design
The study is designed as a single-arm, prospective, inter-
ventional, non-therapeutic study to assess the value of
FDG PET-CT in defining tumor metabolic progression
in patients with mCRC during a period without treat-
ment (see Figure 1 for an overview of the study design).
Objectives
The primary objective of the study is to assess the spon-
taneous TMPI measured by serial FDG PET-CT without
any intercurrent antitumor therapy as a prognostic factor
for OS in patients with mCRC.
Secondary objectives are 1) to test TMPI as a prognostic
marker for PFS; 2) to assess the prognostic value of base-
line tumor FDG uptake on PFS and OS; 3) to compare
TMPI to classical clinico-biological assessment of prog-
nosis; and 4) to test the prognostic value of MRI-based
apparent diffusion coefficient (ADC) and variation of
vADC using voxel-based diffusion maps on OS and PFS.
Exploratory (translational) objectives are 1) to identify
and quantify tumor-specific alterations in plasma DNA
using NGS; 2) to characterize which of these tumor-specific
alterations in plasma DNA form genomic and epigenetic
determinants of tumor metabolic progression guided by
FDG PET-CT; 3) to identify these tumor-specific alterations
in previous tumor tissue; 4) to analyze whether CTC levels
correlate with tumor metabolic progression guided by FDG
PET-CT; and finally 5) to assess the prognostic value of
CTCs on OS.
Patient selection criteria
Baseline metabolic measurements for documentation of
metabolic measurable disease by FDG PET-CT must be
taken at study entry. Laboratory tests required for eligibil-
ity must be completed within 14 days prior to study entry.
Inclusion criteria
Participants must have histologically confirmed CRC that
is metastatic or unresectable and for which standard treat-
ments do not exist or are no longer effective. In addition,
patients should:
 be potential candidates for a Phase I study;
 have been treated with or be intolerant to all
standard chemotherapeutic agents
(fluoropyrimidines, irinotecan and oxaliplatin) and
monoclonal antibodies (bevacizumab, cetuximab
and/or panitumumab, regorafenib if available);
 have signed a written informed consent (approved
by an Independent Ethics Committee [IEC]) and
Figure 1 Study design. TTP = time to progression, SUV = Standardized Uptake Value; TLG = Total Lesion Glycolysis, mCRC = metastatic ColoRectal
Cancer, FDG-PET: FluoroDeoxyGlucose-Positron Emission Tomography, DW-MRI = Diffusion-Weighted Magnetic Resonance Imaging, CTC: Circulating
Tumor Cells).
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procedures;
 be aged 18 or older;
 have a life expectancy greater than 12 weeks;
 have an ECOG performance status ≤ 1;
 and show normal organ and marrow function as
follows: total bilirubin within 2 × normal
institutional upper limits, AST/ALT/Alk
phosphatases levels < 5 × normal institutional upper
limits, creatinine within 2 × normal institutional
upper limits, or creatinine clearance > 35 mL/min.
 Women of child-bearing potential and men must
agree to use adequate contraception (hormonal
or barrier method of birth control, abstinence)
prior to study entry and for the duration of study
participation. Should a woman become pregnant
or suspect she is pregnant while participating in
this study, she must inform her treating physician
immediately.
Exclusion criteria
In addition to pregnant or breast-feeding women, excluded
from the study are patients identified with any of the
following conditions or characteristics:
 chemotherapy or radiotherapy within 4 weeks prior
to entering the study or incomplete recovery from
adverse events due to agents administered more
than 4 weeks earlier.
 treatment with any experimental agents during the
assessment time period.
 uncontrolled brain metastases. bleeding diathesis, history of cardiovascular ischemic
disease, or cerebrovascular incident within the last
six months.
 major surgery within four weeks.
 uncontrolled concurrent illness including, but not
limited to, ongoing or active infection, symptomatic
congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, psychiatric illness or any
significant disease which, in the investigator’s
opinion, would exclude the patient from the study.
 uncontrolled diabetes.
 a history of a different malignancy, except for the
following circumstances: individuals with a history
of other malignancies are eligible if they have been
disease-free for at least 5 years and are deemed by
the investigator to be at low risk for recurrence of
that malignancy. Individuals with the following
cancers are eligible if diagnosed and treated within
the past 5 years: cervical cancer in situ, and basal
cell or squamous cell carcinoma of the skin.
 contra-indications to the use of MRI: cardiac
stimulator implanted cardiac wires, any implanted
electronic devices, or intra-ocular metallic foreign
bodies.
 a previous history of hypersensitivity to iodinated
contrast media.
 medical, geographical, sociological, psychological or
legal conditions that would not permit the patient to
complete the study or sign informed consent.
FDG-PET/CT imaging
Increased glycolysis is one of the hallmarks of cancer.
FDG, an analogue of glucose labeled with a positron
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cancer cells of many tumor types. The positrons emitted
by the FDG are detected by a dedicated camera, enabling
the visualization of cellular glycolytic activity [37]. Serial
FDG PET-CT consists of performing a scan at baseline
(day 1) and after 2 weeks (day 15). The two PET-CTs
need to be performed in strictly identical and standardized
conditions.
The practical guidelines for FDG PET-CT imaging
(activity injected; acquisition timing; processing; image
analysis; PET-CT data form input) are specified in the
Standard Procedure Imaging Manual (SPIM) for PET-CT,
following as closely as possible the EANM procedure
guidelines for tumor PET imaging [38]. Measurement of
several FDG PET-CT metabolic parameters such as SUV,
FTV and TLG for analysis will be documented. To respect
FDG PET quantifications, an ultra-low dose CT (approx 1
mSv) will be performed to correct the metabolic images.
Magnetic resonance imaging
The technical protocol will include T1 and T2 weighted
images without contrast and a diffusion-weighted sequence
with area under the curve calculation made on 2 B values
with the first being superior to 150 ms to eliminate the fast
component (microvessel-related) in order to get an expres-
sion of the true water diffusion properties of the tissue.
The second B value will range between 800 and 1200 ms.
The duration of this non-contrast imaging examination is
about 20 minutes per patient. Volumetric, voxel-based
vADC values will be computed with dedicated software at
the sponsor institution (Institut Jules Bordet). ROI-based
mean ADC value at the larger non-necrotic part of the
lesion will also be determined.
Genomic alterations
To detect tumor-specific alterations in plasma DNA via
NGS technology, blood samples for plasma preparation
will be collected at baseline (2 × 9 mL) and at 2 weeks
(2 × 9 mL) after the start of the study (see Figure 1).
An extra 9 mL whole blood sample will be collected at
baseline in order to distinguish somatic from germline
mutations. Extracted DNA samples will be used for further
analysis using NGS. DNA will also be extracted from previ-
ously available tumor biopsies of the included patients in
order to identify and quantify tumor-specific alterations.
Circulating tumor cells
For CTC quantification, a 9 mL peripheral blood sample
from each patient will be collected and sent at room
temperature to the laboratory responsible for CTC de-
tection at baseline and at 2 weeks after the start of the
study (see Figure 1). These blood samples will be proc-
essed using Veridex, LLC,CellSearch®, and the identifi-
cation and counting of CTCs will be performed withthe CellSpotter™Analyzer, which is a semi-automated
fluorescence-based microscopy system that permits
computer-generated reconstruction of cellular images.
The laboratory investigators will be blinded to the clin-
ical status of the patients.
Follow-up
Follow-up procedures, performed every 2 months after
the second PET-CT assessment, will include physical exam-
ination, vital signs and ECOG performance status, labora-
tory tests and diffusion-weighted MRI.
Statistical considerations
Our primary analysis will consist of the assessment of
the prognostic value of TMPI (evolution of the tumor
FDG uptake from baseline to 2 weeks later) on OS. The
patients will be divided into 2 groups using the observed
median as threshold. The primary comparison will be
done using Kaplan-Meier estimates of OS distributions
and comparison using the log rank test (2-sided level of 5%).
Based on published data from our team [19], we believe that
a HR of .40 favoring patients with slow growing tumors
could be expected and would have a clinically pertinent
value. In order to detect such a HR if true, with a power of
80%, we need to have complete follow-up (observation until
death) for 37 patients. Time zero for measuring survival
will be the day of the second FDG PET-CT assessment.
Getting this number of events, assuming a median
survival of 4 months for the overall population (i.e., we
anticipate a median of 5.7 months for the patients with
slow growing tumors and 2.3 months for the other pa-
tients), should be feasible with an accrual of 3 to 4 patients
per month and registration of 47 patients with a FDG
PET-CT evaluation after 2 weeks. An increase in sample
size to 53 patients should compensate for the fact that not
all patients will have a second FDG PET-CT assessment
or at least one metabolic measurable lesion.
Analysis of the primary objective will be conducted




The principal investigator ensures that this study con-
forms to the Declaration of Helsinki (available at http://
www.wma.net/en/30publications/10policies/b3/) or the
laws and regulations of the country, whichever provides
the greatest protection of the patient.
The study follows the International Conference on
Harmonization E 6 (R1) Guideline for Good Clinical
Practice, reference number CPMP/ICH/135/95 (available at
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf).
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Discussion
Tumor aggressiveness is one of the major determinants
of patient outcome in advanced disease. Despite its
importance, supported by findings reported in the lit-
erature of extreme outcomes for patients with mCRC
treated with chemotherapy, no objective tool allows
clinicians to base treatment decisions on this factor.
The CORIOLAN study will characterize TMPI using
FDG-PET-based metabolic imaging of patients with che-
morefractory mCRC during a period of time without
treatment. Results will be correlated to other assessment
tools like DW-MRI, CTCs and circulating DNA, with
the aim to provide usable tools in daily practice and in
clinical studies in the future.
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